Cargando…

Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol

INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (IC...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Sufei, Wang, Miao, Si, Jinhua, Zhang, Tianyi, Cui, Hong, Gao, Xiumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855296/
https://www.ncbi.nlm.nih.gov/pubmed/29463592
http://dx.doi.org/10.1136/bmjopen-2017-020434
_version_ 1783307070614798336
author He, Sufei
Wang, Miao
Si, Jinhua
Zhang, Tianyi
Cui, Hong
Gao, Xiumei
author_facet He, Sufei
Wang, Miao
Si, Jinhua
Zhang, Tianyi
Cui, Hong
Gao, Xiumei
author_sort He, Sufei
collection PubMed
description INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (ICD-10). Hyperkinetic disorder includes more severe conditions. Ginkgo preparations are used in the treatment of ADHD. The present study will assess the efficacy and safety of ginkgo preparations in the treatment of ADHD in the currently published literature. MATERIALS AND METHODS: All prospective randomised controlled trials (RCTs) will be included in this systematic review. Patients diagnosed with ADHD according to American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), ICD-10 or Chinese Classification and Diagnosis of Mental Diseases third edition (CMDD) will be included. A comprehensive search for RCTs to evaluate the effectiveness and tolerance of ginkgo preparations will be performed. The primary outcomes are the ADHD Rating Scale-IV and Revised Conners’ Parent Rating Scale. The secondary outcomes are quality of life evaluated by the KINDL scale, adverse effects/events, Conners’ Teacher Rating Scale, Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour Scale and Fremdbeurteilungsbogen für Hyperkinetische Störungen. Exclusion criteria are the following: (1) case reports, not randomised trial, non-comparative studies and (2) patients who were not diagnosed based on DSM-IV, DSM-5, ICD-10 or CMDD. The following databases will be searched from their inception until January 2018: Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, China Biology Medicine Disc, China National Knowledge Infrastructure Database, Wanfang Database and Chinese Scientific Journals Database. Two authors will independently perform the study selection, extract the data and assess the study quality and risk of bias. ETHICS AND DISSEMINATION: This systematic review does not require ethics approval. It will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42017077190.
format Online
Article
Text
id pubmed-5855296
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58552962018-03-19 Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol He, Sufei Wang, Miao Si, Jinhua Zhang, Tianyi Cui, Hong Gao, Xiumei BMJ Open Complementary Medicine INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (ICD-10). Hyperkinetic disorder includes more severe conditions. Ginkgo preparations are used in the treatment of ADHD. The present study will assess the efficacy and safety of ginkgo preparations in the treatment of ADHD in the currently published literature. MATERIALS AND METHODS: All prospective randomised controlled trials (RCTs) will be included in this systematic review. Patients diagnosed with ADHD according to American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), ICD-10 or Chinese Classification and Diagnosis of Mental Diseases third edition (CMDD) will be included. A comprehensive search for RCTs to evaluate the effectiveness and tolerance of ginkgo preparations will be performed. The primary outcomes are the ADHD Rating Scale-IV and Revised Conners’ Parent Rating Scale. The secondary outcomes are quality of life evaluated by the KINDL scale, adverse effects/events, Conners’ Teacher Rating Scale, Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour Scale and Fremdbeurteilungsbogen für Hyperkinetische Störungen. Exclusion criteria are the following: (1) case reports, not randomised trial, non-comparative studies and (2) patients who were not diagnosed based on DSM-IV, DSM-5, ICD-10 or CMDD. The following databases will be searched from their inception until January 2018: Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, China Biology Medicine Disc, China National Knowledge Infrastructure Database, Wanfang Database and Chinese Scientific Journals Database. Two authors will independently perform the study selection, extract the data and assess the study quality and risk of bias. ETHICS AND DISSEMINATION: This systematic review does not require ethics approval. It will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42017077190. BMJ Publishing Group 2018-02-20 /pmc/articles/PMC5855296/ /pubmed/29463592 http://dx.doi.org/10.1136/bmjopen-2017-020434 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Complementary Medicine
He, Sufei
Wang, Miao
Si, Jinhua
Zhang, Tianyi
Cui, Hong
Gao, Xiumei
Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title_full Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title_fullStr Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title_full_unstemmed Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title_short Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
title_sort efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
topic Complementary Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855296/
https://www.ncbi.nlm.nih.gov/pubmed/29463592
http://dx.doi.org/10.1136/bmjopen-2017-020434
work_keys_str_mv AT hesufei efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol
AT wangmiao efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol
AT sijinhua efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol
AT zhangtianyi efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol
AT cuihong efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol
AT gaoxiumei efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol